CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.
Investors 2
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| 10.11.2022 | Red Tree V... | redtreevc.... |
Mentions in press and media 3
| Date | Title | Description |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 01.03.2023 | Cargo Therapeutics Raises $200M in Upsized Series A Financing | Cargo Therapeutics, Inc., a San Mateo, CA-based biotechnology company advancing a next generation of CAR T-cell therapies for cancer, closed a $200m upsized Series A financing. The round was co-led by Third Rock Ventures, RTW Investments, L... |
| - | CARGO Therapeutics | “CARGO is engineering best-in-class CARs that overcome resistance and address barriers to access so that more patients benefit from potentially curative therapies. News CARGO Therapeutics Now Hiring. Join us to make a difference.Open Positi... |